- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Fall 2015
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Gilead Sciences, Inc. v. Lupin Pharms., Inc., 15-1956 (D. Md.) | July 1, 2015 | Hon. J. Frederick Motz | Tamiflu® (oseltamivir phosphate capsules) | 5,763,483 |
| Otsuka Pharm. Co., Ltd. v. MaCleods Pharms. Ltd., 15-5109 (D.N.J.) | July 2, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,759,350
|
| Dr. Reddy’s Labs., Ltd. v. Helsinn Healthcare S.A., IPR2015-01550 (PTAB) | July 3, 2015 | N/A | Aloxi® (palonosetron hydrochloride for injection) | 8,729,094 |
| Dr. Reddy’s Labs., Ltd. v. Helsinn Healthcare S.A., IPR2015-01551 (PTAB) | July 3, 2015 | N/A | Aloxi® (palonosetron hydrochloride for injection) | 8,729,094 |
| Dr. Reddy’s Labs., Ltd. v. Helsinn Healthcare S.A., IPR2015-01553 (PTAB) | July 3, 2015 | N/A | Aloxi® (palonosetron hydrochloride for injection) | 8,729,094 |
| Dr. Reddy’s Labs., Ltd. v. Helsinn Healthcare S.A., IPR2015-01554 (PTAB) | July 3, 2015 | N/A | Aloxi® (palonosetron hydrochloride for injection) | 8,729,094 |
| Eli Lilly and Co. v. Lupin Pharms., Inc., 15-1047 (S.D. Ind.) | July 6, 2015 | Hon. Sarah Evans Barker | Axiron® (testosterone metered transdermal solution) |
8,419,307
8,177,449
8,435,944
8,807,861
8,993,520
|
| Prinston Pharm., Inc. v. Noven Therapeutics, LLC, 15-5308 (D.N.J.) | July 7, 2015 | Hon. Claire C. Cecchi | Brisdelle® (paroxetine mesylate capsules) | 8,946,251 |
| Eli Lilly and Co. v. Lupin Pharms., Inc., 15-0877 (E.D. Va.) | July 6, 2015 | Hon. Anthony J. Trenga | Axiron® (testosterone metered transdermal solution) |
8,419,307
8,177,449
8,435,944
8,807,861
8,993,520
|
| Celgene Corp. v. Teva Pharms. USA, Inc., 15-0589 (D. Del.) | July 10, 2015 | Hon. Richard G. Andrews | Istodax® (romidepsin for injection) |
7,608,280
7,611,724
|
| R-Tech Ueno, Ltd. v. Apotex, Inc., 15-0592 (D. Del.) | July 10, 2015 | Hon. Sue L. Robinson | Rescula® (unoprostone isopropyl ophthalmic solution) |
6,770,675
6,458,836
|
| Eli Lilly and Co. v. Mylan Labs. Ltd., 15-1083 (S.D. Ind.) | July 10, 2015 | Hon. Sarah Evans Barker | Alimta® (pemetrexed for injection) | 7,772,209 |
| Fresenius Kabi USA, LLC v. Cubist Pharms., Inc., IPR2015-01566 (PTAB) | July 10, 2015 | N/A | Cubicin® (daptomycin for injection) | 8,129,342 |
| Fresenius Kabi USA, LLC v. Cubist Pharms., Inc., IPR2015-01570 (PTAB) | July 10, 2015 | N/A | Cubicin® (daptomycin for injection) | 8,058,238 |
| Fresenius Kabi USA, LLC v. Cubist Pharms., Inc., IPR2015-01571 (PTAB) | July 10, 2015 | N/A | Cubicin® (daptomycin for injection) | 8,058,238 |
| Fresenius Kabi USA, LLC v. Cubist Pharms., Inc., IPR2015-01572 (PTAB) | July 10, 2015 | N/A | Cubicin® (daptomycin for injection) | 8,058,238 |
| Senju Pharm. Co., Ltd. v. Watson Labs., Inc., 15-5591 (D.N.J.) | July 16, 2015 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
|
| Gilead Sciences, Inc. v. Sigmapharm Labs., LLC, 15-3950 (E.D. Pa.) | July 16, 2015 | Hon. Gerald J. Pappert | Letairis® (ambrisentan tablets) | RE42,462 |
| Meda Pharms Inc. v. Amneal Pharms. LLC, 15-0617 (D. Del.) | July 17, 2015 | Hon. Gregory M. Sleet | Astepro® (azelastine hydrochloride nasal spray) |
8,071,073
8,518,919
|
| Roxane Labs., Inc. v. Novel Labs., Inc., 15-5618 (D.N.J.) | July 17, 2015 | Hon. Stanley R. Chesler | Phoslo® (calcium acetate tablet) | 8,563,032 |
| Jazz Pharms., Inc. v. Wockhardt Bio AG, 15-5619 (D.N.J.) | July 17, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
6,472,431
6,780,889
7,262,219
7,851,506
8,263,650
8,324,275
8,461,203
7,668,730
7,765,106
7,765,107
7,895,059
8,457,988
8,589,182
8,731,963
8,772,306
8,859,619
8,952,062
|
| Spectrum Pharms., Inc. v. Actavis LLC, 15-1360 (D. Nev.) | July 17, 2015 | Hon. James C. Mahan | Fusilev® (levoleucovorin calcium for injection) | 6,500,829 |
| Alcon Research, Ltd. v. Lupin Ltd., 15-0621 (D. Del.) | July 20, 2015 | Hon. Sue L. Robinson | Travatan Z® (travoprost ophthalmic solution) |
8,268,299
8,323,630
8,388,941
|
| United Therapeutics Corp. v. Watson Labs., Inc., 15-5723 (D.N.J.) | July 22, 2015 | Hon. Peter G. Sheridan | Tyvaso® (treprostinil inhalation solution) |
6,521,212
6,756,033
8,497,393
|
| Alcon Pharms. Ltd. v. Dr. Reddy’s Labs., Inc., 15-5756 (D.N.J.) | July 24, 2015 | Hon. Peter G. Sheridan | Ciprodex® (ciprofloxacin / dexamethasone otic suspension) |
6,284,804
6,359,016
|
| Lannett Holdings, Inc. v. AstraZeneca AB, IPR2015-01629 (PTAB) | July 28, 2015 | N/A | Zomig® (zolmitriptan nasal spray) | 6,750,237 |
| Lannett Holdings, Inc. v. AstraZeneca AB, IPR2015-01630 (PTAB) | July 28, 2015 | N/A | Zomig® (zolmitriptan nasal spray) | 7,220,767 |
| Mylan Pharma Acquisition LTD v. Fresenius Kabi USA, LLC, 15-6700 (N.D. Ill.) | July 30, 2015 | Hon. Rebecca R. Pallmeyer | Ultiva® (remifentanil hydrochloride for Injection) | 5,866,591 |
| Janssen Pharmaceutica N.V. v. Fera Pharms., LLC, 15-5997 (S.D.N.Y.) | July 30, 2015 | Hon. P. Kevin Castel | Sporanox® (itraconazole oral solution) | 6,407,079 |
| Cosmo Technologies Ltd. v. Lupin Ltd., 15-0669 (D. Del.) | July 31, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
RE43,799
|
| Galderma Labs., L.P. v. Dr. Reddy’s Labs., Ltd., 15-0670 (D. Del.) | July 31, 2015 | Hon. Leonard P. Stark | Oracea® (doxycycline capsules) |
7,211,267
7,232,572
8,603,506
7,749,532
8,206,740
8,394,405
8,394,406
8,470,364
8,709,478
|
| BTG Int’l Ltd. v. Actavis Labs. FL, Inc., 15-5909 (D.N.J.) | July 31, 2015 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) |
5,604,213
8,822,438
|
| Validus Pharms. LLC v. Aurobindo Pharma Ltd., 15-5912 (D.N.J.) | July 31, 2015 | Hon. Michael A. Shipp | Equetro® (carbamazepine extended-release capsules) | 6,977,253 |
| Sawai USA, Inc. v. Nissan Chemical Industries Ltd., IPR2015-01647 (PTAB) | July 31, 2015 | N/A | Livalo® (pitavastatin calcium tablets) | 5,856,336 |
| Sawai USA, Inc. v. Nissan Chemical Industries Ltd., IPR2015-01648 (PTAB) | July 31, 2015 | N/A | Livalo® (pitavastatin calcium tablets) | 5,856,336 |
| Janssen Biotech, Inc. v. Amneal Pharms. LLC, 15-0679 (D. Del.) | Aug. 3, 2015 | Hon. Sue L. Robinson | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| BTG International Ltd. v. Actavis Labs. FL, Inc., 15-81076 (S.D. Fla.) | Aug. 3, 2015 | Hon. Donald M. Middlebrooks | Zytiga® (abiraterone acetate tablets) |
5,604,213
8,822,438
|
| Boehringer Ingelheim Pharms. Inc. v. HEC Pharm Group, 15-5982 (D.N.J.) | Aug. 4, 2015 | Hon. Peter G. Sheridan |
Tradjenta® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
7,407,955
8,119,648
8,178,541
8,673,927
8,846,695
8,853,156
|
| Janssen Biotech, Inc. v. Mylan Pharms. Inc., 15-0130 (N.D.W.V.) | Aug. 4, 2015 | Hon. Irene M. Keeley | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Purdue Pharma L.P. v. Actavis Labs. FL, Inc., 15-0686 (D. Del.) | Aug. 5, 2015 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
6,733,783
8,361,499
8,551,520
8,647,667
9,023,401
8,529,948
8,808,740
8,309,060
|
| Purdue Pharma L.P. v. Alvogen Pine Brook, Inc., 15-0687 (D. Del.) | Aug. 5, 2015 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
6,733,783
8,361,499
8,551,520
8,647,667
9,023,401
8,529,948
8,808,740
8,309,060
|
| AstraZeneca AB v. HEC Pharm Co., Ltd., 15-6025 (D.N.J.) | Aug. 5, 2015 | Hon. Mary L. Cooper | Nexium® (esomeprazole magnesium delayed-release tablets) |
6,369,085
7,411,070
8,466,175
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 15-13099 (D. Mass.) | Aug. 6, 2015 | Hon. F. Dennis Saylor, IV |
OxyContin® (oxycodone extended-release tablets)
Xtampza ER™ (oxycodone extended-release capsules)
|
7,674,799
7,674,800
7,683,072
8,652,497
|
| Purdue Pharm. Products L.P. v. Lannett Holdings, Inc., 15-6036 (D.N.J.) | Aug. 6, 2015 | Hon. Susan D. Wigenton | Dilaudid® (hydromorphone hydrochloride oral solution) | 6,589,960 |
| AstraZeneca Pharms. LP v. Agila Specialties, Inc., 15-6039 (D.N.J.) | Aug. 6, 2015 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 15-6075 (D.N.J.) | Aug. 6, 2015 | Hon. Peter G. Sheridan | Noxafil® (posaconazole delayed-release tablets) | 5,661,151 |
| Collegium Pharm., Inc. v. Purdue Pharma L.P., 15-6179 (S.D.N.Y.) | Aug. 6, 2015 | Hon. Katherine B. Forrest |
OxyContin® (oxycodone extended-release tablets)
Xtampza ER™ (oxycodone extended-release capsules)
|
7,674,799
7,674,800
7,683,072
8,652,497
|
| Eli Lilly and Co. v. Emcure Pharms Ltd., 15-1244 (S.D. Ind.) | Aug. 7, 2015 | Hon. Jane Magnus-Stinson | Alimta® (pemetrexed for injection) | 7,772,209 |
| AstraZeneca AB v. Lupin Ltd., 15-6092 (D.N.J.) | Aug. 7, 2015 | Hon. Mary L. Cooper | Nexium 24HR® (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
|
| Coalition for Affordable Drugs VII LLC v. Pozen Inc., IPR2015-01680 (PTAB) | Aug. 7, 2015 | N/A | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 8,852,636 |
| Hospira, Inc. v. Amneal Pharms. LLC, 15-0697 (D. Del.) | Aug. 11, 2015 | Hon. Richard G. Andrews | Precedex® (dexmedetomidine hydrochloride injection) |
8,242,158
8,338,470
8,455,527
8,648,106
|
| Par Pharm., Inc. v. TWi Pharms., Inc., 15-0698 (D. Del.) | Aug. 11, 2015 | Hon. Sue L. Robinson | Megace® ES (megestrol acetate oral suspension) |
9,101,540
9,101,549
|
| Boehringer Ingelheim Pharms. Inc. v. Intas Pharms., Ltd., 15-0664 (M.D.N.C.) | Aug. 11, 2015 | Hon. Catherine C. Eagles | Jentadueto® (linagliptin / metformin hydrochloride tablets) |
8,673,927
8,846,695
|
| Horizon Pharma Ireland Ltd v. Actavis Labs. UT, Inc., 15-6131 (D.N.J.) | Aug. 11, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,101,591 |
| Horizon Pharma Ireland Ltd v. Amneal Pharms. LLC, 15-6132 (D.N.J.) | Aug. 11, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,101,591 |
| Horizon Pharma Ireland Ltd v. IGI Labs., Inc., 15-6134 (D.N.J.) | Aug. 11, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,101,591 |
| Horizon Pharma Ireland Ltd v. Taro Pharms. USA, Inc., 15-6135 (D.N.J.) | Aug. 11, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,101,591 |
| Coalition for Affordable Drugs VII LLC v. Horizon Pharma USA, Inc., IPR2015-01718 (PTAB) | Aug. 12, 2015 | N/A | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 8,945,621 |
| Millennium Pharms., Inc. v. Pharmascience Inc., 15-0702 (D. Del.) | Aug. 13, 2015 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| Coalition for Affordable Drugs IX LLC v. Bristol-Myers Squibb Co., IPR2015-01723 (PTAB) | Aug. 13, 2015 | N/A | Eliquis® (apixaban tablets) | 6,967,208 |
| Noven Therapeutics, LLC v. Actavis Labs. FL, Inc., 15-6225 (D.N.J.) | Aug. 14, 2015 | Hon. Claire C. Cecchi | Brisdelle® (paroxetine mesylate capsules) | 8,946,251 |
| Vivus, Inc. v. Actavis Labs. FL, Inc., 15-6256 (D.N.J.) | Aug. 17, 2015 | Hon. Stanley R. Chesler | Qsymia® (phentermine / topiramate extended-release capsules) |
9,011,905
9,011,906
|
| Par Pharm., Inc. v. TWi Pharms., Inc., 15-0710 (D. Del.) | Aug. 18, 2015 | Hon. Sue L. Robinson | Megace® ES (megestrol acetate oral suspension) | 9,107,827 |
| Dr. Reddy’s Labs., Inc. v. Fresenius Kabi USA, LLC, 15-0714 (D. Del.) | Aug. 18, 2015 | Hon. Richard G. Andrews | Diprivan® (propofol injectable emulsion) | 8,476,010 |
| Lupin Ltd. v. Pozen, Inc., IPR2015-01773 (PTAB) | Aug. 19, 2015 | N/A | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 8,858,996 |
| Lupin Ltd. v. Pozen, Inc., IPR2015-01774 (PTAB) | Aug. 19, 2015 | N/A | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 8,852,636 |
| Lupin Ltd. v. Pozen, Inc., IPR2015-01775 (PTAB) | Aug. 19, 2015 | N/A | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 8,865,190 |
| Coalition for Affordable Drugs X LLC v. Anacor Pharms., Inc., IPR2015-01776 (PTAB) | Aug. 20, 2015 | N/A | Kerydin® (Tavaborole topical solution) | 7,582,621 |
| Dr. Reddy’s Labs., Ltd. v. Galderma Labs., Inc., IPR2015-01777 (PTAB) | Aug. 20, 2015 | N/A | Oracea® (doxycycline capsules) | 8,603,506 |
| Dr. Reddy’s Labs., Ltd. v. Galderma Labs., Inc., IPR2015-01778 (PTAB) | Aug. 20, 2015 | N/A | Oracea® (doxycycline capsules) | 8,603,506 |
| Coalition for Affordable Drugs X LLC v. Anacor Pharms., Inc., IPR2015-01780 (PTAB) | Aug. 20, 2015 | N/A | Kerydin® (Tavaborole topical solution) | 7,767,657 |
| Dr. Reddy’s Labs., Ltd. v. Galderma Labs., Inc., IPR2015-01782 (PTAB) | Aug. 20, 2015 | N/A | Oracea® (doxycycline capsules) | 8,603,506 |
| Coalition for Affordable Drugs X LLC v. Anacor Pharms., Inc., IPR2015-01785 (PTAB) | Aug. 20, 2015 | N/A | Kerydin® (Tavaborole topical solution) | 7,767,657 |
| Merck Sharp & Dohme Corp. v. Savior Lifetec Corp., 15-0415 (E.D.N.C.) | Aug. 21, 2015 | Hon. Terrence W. Boyle | Invanz® (ertapenem for injection) | 5,952,323 |
| Otsuka Pharm. Co., Ltd. v. Standard Chem. & Pharm. Co., Ltd., 15-6353 (D.N.J.) | Aug. 21, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,759,350
|
| Sumitomo Dainippon Pharma Co., Ltd. v. Teva Pharms. USA, Inc., 15-6401 (D.N.J.) | Aug. 24, 2015 | Hon. Stanley R. Chesler | Latuda® (lurasidone hydrochloride tablets) | 5,532,372 |
| Allergan Inc, v. Teva Pharms. USA, Inc., 15-1455 (E.D. Tex.) | Aug. 24, 2015 | Hon. Rodney Gilstrap | Restasis® (cyclosporine ophthalmic emulsion) |
8,629,111
8,633,162
8,642,556
8,648,048
8,685,930
|
| Coalition for Affordable Drugs XI LLC v. Insys Pharma, Inc., IPR2015-01797 (PTAB) | Aug. 24, 2015 | N/A | Subsys® (fentanyl sublingual spray) | 8,835,459 |
| Coalition for Affordable Drugs XI LLC v. Insys Pharma, Inc., IPR2015-01799 (PTAB) | Aug. 24, 2015 | N/A | Subsys® (fentanyl sublingual spray) | 8,835,460 |
| Coalition for Affordable Drugs XI LLC v. Insys Pharma, Inc., IPR2015-01800 (PTAB) | Aug. 24, 2015 | N/A | Subsys® (fentanyl sublingual spray) | 8,486,972 |
| Cephalon, Inc. v. Panacea Biotec, Ltd., 15-0735 (D. Del.) | Aug. 25, 2015 | Hon. Sue L. Robinson | Treanda® (bendamustine hydrochloride for infusion) |
8,445,524
8,791,270
8,669,279
8,883,836
8,895,756
|
| Boehringer Ingelheim Pharms. Inc. v. Mylan Pharms., Inc., 15-0145 (N.D.W.V.) | Aug. 25, 2015 | Hon. John Preston Bailey |
Tradjenta® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
8,673,927
8,846,695
8,853,156
|
| The Medicines Co. v. Sagent Pharms., Inc., 15-7507 (N.D. Ill.) | Aug. 26, 2015 | Hon. Harry D. Leinenweber | Angiomax® (bivalirudin for injection) |
7,582,727
7,598,343
|
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-01810 (PTAB) | Aug. 26, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,895,059 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-01817 (PTAB) | Aug. 26, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,457,988 |
| Forest Labs., LLC v. Amneal Pharms. LLC, 15-0756 (D. Del.) | Aug. 27, 2015 | Hon. Leonard P. Stark | Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) |
8,039,009
8,058,291
8,168,209
8,173,708
8,283,379
8,293,794
8,329,752
8,338,485
8,338,486
8,362,085
8,580,858
8,598,233
|
| Wockhardt Bio AG v. Jazz Pharms., Inc., IPR2015-01813 (PTAB) | Aug. 27, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,589,182 |
| Wockhardt Bio AG v. Jazz Pharms., Inc., IPR2015-01814 (PTAB) | Aug. 27, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,457,988 |
| Wockhardt Bio AG v. Jazz Pharms., Inc., IPR2015-01815 (PTAB) | Aug. 27, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,765,106 |
| Wockhardt Bio AG v. Jazz Pharms., Inc., IPR2015-01816 (PTAB) | Aug. 27, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,895,059 |
| Wockhardt Bio AG v. Jazz Pharms., Inc., IPR2015-01818 (PTAB) | Aug. 27, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,668,730 |
| Wockhardt Bio AG v. Jazz Pharms., Inc., IPR2015-01820 (PTAB) | Aug. 27, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,765,107 |
| Warner Chilcott (US), LLC v. Teva Pharms. USA, Inc., 15-1471 (E.D. Tex.) | Aug. 28, 2015 | Hon. Rodney Gilstrap | Delzicol® (mesalamine delayed-release capsules) | 6,649,180 |
| Galderma Labs., L.P. v. Taro Pharms. U.S.A., Inc., 15-2814 (N.D. Tex.) | Aug. 28, 2015 | Hon. Ed Kinkeade | Epiduo® (adapalene /benzoyl peroxide gel) |
8,071,644
8,080,537
8,129,362
8,445,543
8,809,305
|
| Coalition for Affordable Drugs VIII LLC v. The Trustees of The University of Pennsylvania, IPR2015-01835 (PTAB) | Aug. 28, 2015 | N/A | Juxtapid® (lomitapide mesylate capsules) | 8,618,135 |
| Coalition for Affordable Drugs VIII LLC v. The Trustees of The University of Pennsylvania, IPR2015-01836 (PTAB) | Aug. 28, 2015 | N/A | Juxtapid® (lomitapide mesylate capsules) | 7,932,268 |
| Janssen Pharmaceutica, N.V. v. Mylan Pharms., Inc., 15-0760 (D. Del.) | Aug. 31, 2015 | Hon. Sue L. Robinson | Complera® (emtricitabine / rilpivirine hydrochloride / tenofovir disoproxil fumarate tablets) |
8,841,310
7,125,879
8,101,629
|
| Warner Chilcott (US), LLC v. Teva Pharms. USA, Inc., 15-0761 (D. Del.) | Aug. 31, 2015 | Hon. Gregory M. Sleet | Delzicol® (mesalamine delayed-release capsules) | 6,649,180 |
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 15-6541 (D.N.J.) | Aug. 31, 2015 | Hon. William H. Walls | Dificid® (fidaxomicin tablets) |
7,906,489
8,586,551
7,378,508
7,863,249
8,859,510
|
| Gilead Sciences, Inc. v. Mylan Inc., 15-0149 (N.D.W.V.) | Aug. 31, 2015 | Hon. Irene M. Keeley | Complera® (emtricitabine / rilpivirine hydrochloride / tenofovir disoproxil fumarate tablets) |
6,642,245
6,703,396
8,592,397
8,716,264
|
| Jazz Pharms., Inc. v. Lupin Ltd., 15-6548 (D.N.J.) | Sept. 1, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
6,472,431
6,780,889
7,262,219
7,851,506
8,263,650
8,324,275
8,461,203
7,668,730
7,765,106
7,765,107
7,895,059
8,457,988
8,589,182
8,731,963
8,772,306
8,859,619
8,952,062
9,050,302
|
| Osi Pharms., LLC v. Apotex Inc., 15-0772 (D. Del.) | Sept. 2, 2015 | Hon. Sue L. Robinson | Tarceva® (erlotinib hydrochloride tablets) | 6,900,221 |
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 15-61858 (S.D. Fla.) | Sept. 2, 2015 | Hon. Kathleen M. Williams | Dificid® (fidaxomicin tablets) |
7,906,489
8,586,551
7,378,508
7,863,249
8,859,510
|
| Omeros Corp. v. Par Sterile Products, LLC, 15-6561 (D.N.J.) | Sept. 2, 2015 | Hon. Jose L. Linares | Omidria® (phenylephrine / ketorolac injection) |
8,173,707
8,586,633
9,066,856
|
| Jazz Pharms., Inc. v. Amneal Pharms. LLC, 15-6562 (D.N.J.) | Sept. 2, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| AstraZeneca AB v. Alkem Labs. Ltd., 15-6609 (D.N.J.) | Sept. 2, 2015 | Hon. Mary L. Cooper | Nexium® (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
8,466, 175
|
| AstraZeneca AB v. Actavis Elizabeth LLC, 15-6610 (D.N.J.) | Sept. 2, 2015 | Hon. Mary L. Cooper | Nexium 24HR® (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
|
| Janssen Pharmaceutica, N.V. v. Mylan Pharms., Inc., 15-0152 (N.D.W.V.) | Sept. 2, 2015 | Hon. Irene M. Keeley | Complera® (emtricitabine / rilpivirine hydrochloride / tenofovir disoproxil fumarate tablets) |
8,841,310
7,125,879
8,101,629
|
| Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc., IPR2015-01850 (PTAB) | Sept. 2, 2015 | N/A | Ampyra® (dalfampridine extended-release tablets) | 8,440,703 |
| Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc., IPR2015-01853 (PTAB) | Sept. 2, 2015 | N/A | Ampyra® (dalfampridine extended-release tablets) | 8,007,826 |
| Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc., IPR2015-01857 (PTAB) | Sept. 2, 2015 | N/A | Ampyra® (dalfampridine extended-release tablets) | 8,663,685 |
| Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc., IPR2015-01858 (PTAB) | Sept. 2, 2015 | N/A | Ampyra® (dalfampridine extended-release tablets) | 8,354,437 |
| Omeros Corp. v. Par Sterile Products, LLC, 15-0773 (D. Del.) | Sept. 3, 2015 | Hon. Richard G. Andrews | Omidria® (phenylephrine / ketorolac injection) |
8,173,707
8,586,633
9,066,856
|
| Spectrum Pharms., Inc. v. Amneal Pharms. LLC, 15-1697 (D. Nev.) | Sept. 3, 2015 | Hon. James C. Mahan | Fusilev® (levoleucovorin calcium for injection) | 6,500,829 |
| Purdue Pharma L.P. v. Alvogen Pine Brook, Inc., 15-0784 (D. Del.) | Sept. 4, 2015 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,056,052
9,060,940
|
| Lupin Ltd. v. Senju Pharm. Co., Ltd., IPR2015-01871 (PTAB) | Sept. 4, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,129,431 |
| Allergan, Inc. v. Innopharma, Inc., 15-1504 (E.D. Tex.) | Sept. 8, 2015 | Hon. Rodney Gilstrap | Restasis® (cyclosporine ophthalmic emulsion) |
8,629,111
8,633,162
8,642,556
8,648,048
8,685,930
|
| Meda Pharms. Inc. v. Teva Pharms. USA, Inc., 15-0785 (D. Del.) | Sept. 8, 2015 | Hon. Leonard P. Stark | Dymista® (azelastine hydrochloride / fluticasone propionate nasal spray) |
8,163,723
8,168,620
|
| Millennium Pharms., Inc. v. Hospira, Inc., 15-0804 (D. Del.) | Sept. 10, 2015 | Hon. Richard G. Andrews | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| Janssen Pharmaceutica N.V. v. Apotex Inc., 15-7121 (S.D.N.Y.) | Sept. 10, 2015 | Hon. William H. Pauley, III | Sporanox® (itraconazole oral solution) | 6,407,079 |
| Kowa Co., Ltd. v. Zydus Pharms. (USA) Inc., 15-7136 (S.D.N.Y.) | Sept. 10, 2015 | Hon. Paul A. Crotty | Livalo® (pitavastatin calcium tablets) | 6,465,477 |
| Merck Sharp & Dohme B.V. v. Teva Pharms. USA, Inc., 15-0806 (D. Del.) | Sept. 11, 2015 | Hon. Gregory M. Sleet | NuvaRing® (ethinyl estradiol / etonogestrel vaginal ring) | 5,989,581 |
| Kowa Co., Ltd. v. Zydus Pharms. (USA) Inc., 15-6792 (D.N.J.) | Sept. 11, 2015 | Hon. Freda L. Wolfson | Livalo® (pitavastatin calcium tablets) | 6,465,477 |
| Depomed, Inc. v. Actavis Elizabeth LLC, 15-6797 (D.N.J.) | Sept. 11, 2015 | Hon. Claire C. Cecchi | Nucynta® ER (tapentadol hydrochloride extended-release tablets) | 8,536,130 |
| Allergan Inc, v. Teva Pharms. USA, Inc., 15-0815 (D. Del.) | Sept. 14, 2015 | Hon. Sue L. Robinson | Restasis® (cyclosporine ophthalmic emulsion) |
8,629,111
8,633,162
8,642,556
8,648,048
8,685,930
|
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-01903 (PTAB) | Sept. 14, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,731,963 |
| Otsuka Pharm. Co., Ltd. v. Hetero USA Inc., 15-0822 (D. Del.) | Sept. 15, 2015 | Hon. Richard G. Andrews | Samsca® (tolvaptan tablets) | 5,753,677 |
| Acorda Therapeutics, Inc. v. Par Pharm., Inc., 15-0824 (D. Del.) | Sept. 15, 2015 | Hon. Leonard P. Stark | Ampyra® (dalfampridine extended-release tablets) |
8,007,826
8,354,437
8,440,703
8,663,685
|
| Gilead Sciences, Inc. v. Lupin Pharms., Inc., 15-2793 (D. Md.) | Sept. 16, 2015 | Hon. J. Frederick Motz | Tamiflu® (oseltamivir phosphate capsules) | 5,763,483 |
| Purdue Pharma L.P. v. Amneal Pharms. LLC, 15-0831 (D. Del.) | Sept. 17, 2015 | Hon. Sue L. Robinson | OxyContin® (oxycodone extended-release tablets) |
9,060,976
9,034,376
|
| Impax Labs., Inc. v. Actavis Labs. FL, Inc., 15-6934 (D.N.J.) | Sept. 17, 2015 | Hon. Katharine S. Hayden | Rytary® (levodopa / carbidopa capsules) |
7,094,427
8,377,474
8,454,998
8,557,283
9,089,607
9,089,608
|
| Horizon Pharma Ireland Ltd. v. Lupin Ltd., 15-6935 (D.N.J.) | Sept. 17, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,132,110 |
| Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 15-6989 (D.N.J.) | Sept. 17, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,132,110 |
| Horizon Pharma Ireland Ltd. v. Amneal Pharms. LLC, 15-6990 (D.N.J.) | Sept. 17, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,132,110 |
| Horizon Pharma Ireland Ltd. v. IGI Labs., Inc., 15-6991 (D.N.J.) | Sept. 17, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,132,110 |
| Bayer Pharma AG v. alembic Pharms. Ltd., 15-0832 (D. Del.) | Sept. 18, 2015 | Hon. Gregory M. Sleet | Staxyn® (vardenafil hydrochloride tablets) | 8,613,950 |
| Vivus, Inc. v. Teva Pharms. USA, Inc., 15-6957 (D.N.J.) | Sept. 18, 2015 | Hon. Stanley R. Chesler | Qsymia® (phentermine / topiramate extended-release capsules) |
9,011,905
9,011,906
|
| AstraZeneca Pharms. LP v. Mylan Pharms. Inc., 15-7009 (D.N.J.) | Sept. 21, 2015 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Astellas Pharma Inc. v. Apotex Inc., 15-0857 (D. Del.) | Sept. 22, 2015 | Hon. Sue L. Robinson | Mycamine® (micafungin sodium for injection) |
6,107,458
6,774,104
|
| Taro Pharms. U.S.A., Inc. v. Perrigo UK Finco Ltd., 15-0859 (D. Del.) | Sept. 22, 2015 | Hon. Richard G. Andrews | Topicort® (desoximetasone topical spray) |
8,277,780
8,715,624
|
| Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, 15-7015 (D.N.J.) | Sept. 23, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, 15-0865 (D. Del.) | Sept. 24, 2015 | Hon. Gregory M. Sleet | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Amneal Pharms. LLC v. Yeda Research and Development Co., Ltd., IPR2015-01976 (PTAB) | Sept. 25, 2015 | N/A | Copaxone® (glatiramer acetate for injection) | 8,232,250 |
| Amneal Pharms. LLC v. Yeda Research and Development Co., Ltd., IPR2015-01980 (PTAB) | Sept. 25, 2015 | N/A | Copaxone® (glatiramer acetate for injection) | 8,399,413 |
| Amneal Pharms. LLC v. Yeda Research and Development Co., Ltd., IPR2015-01981 (PTAB) | Sept. 25, 2015 | N/A | Copaxone® (glatiramer acetate for injection) | 8,969,302 |
| Coalition For Affordable Drugs V LLC v. Biogen MA, Inc., IPR2015-01993 (PTAB) | Sept. 28, 2015 | N/A | Tecfidera® (dimethyl fumarate delayed-release capsule) | 8,399,514 |
| Mylan Pharms. Inc. v. 3M Co., IPR2015-02002 (PTAB) | Sept. 29, 2015 | N/A |
Ventolin HFA® (albuterol sulfate inhalator)
Flovent HFA® (fluticasone propionate inhalator)
Advair HFA® (fluticasone propionate / salmeterol xinafoate inhalator)
|
6,743,413 |
| Salix Pharms., Inc. v. Apotex, Inc., 15-0880 (D. Del.) | Sept. 30, 2015 | Hon. Gregory M. Sleet | Giazo® (balsalazide disodium tablets) |
6,197,341
8,497,256
|
GENERICally Speaking Fall 2015
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.